On August 19, 2026, Morgan Stanley upgrades its rating on Merck (NYSE: MRK) to Overweight. This rating suggests the pharmaceutical stock could perform better than its peers. The firm sets a new price target of $179.00. At the time, Merck was priced at $152.22, indicating a potential upside of about 17.6% for investors.
This positive outlook is driven by a major breakthrough from Merck, a global pharmaceutical company, and its partner Moderna (NASDAQ: MRNA). They announce successful results for their personalized mRNA cancer vaccine, intismeran autogene. When combined with Merck's successful immunotherapy drug, Keytruda, the treatment shows significant promise for cancer patients, marking a significant cancer treatment breakthrough.
The Phase 3 study involved over 1,100 patients with a high-risk form of skin cancer. The results show that patients receiving the vaccine with Keytruda have longer periods before their cancer returns. It also extends the time before the cancer spreads to other parts of the body, a key measure known as distant metastasis-free survival, highlighting the potential of this skin cancer treatment.
The market reacts strongly to this news, which represents the first positive Phase 3 result for an mRNA cancer therapy. Shares of Merck increase by 12.61% to $152.22. The stock of its partner, Moderna, also sees a substantial rise, as highlighted by Zacks Investment Research, reflecting strong biotech investment interest.
Merck's stock trades between $144.90 and $153.43 during the day, approaching its 52-week high of $153.47. The company's market capitalization, which is the total value of all its shares, is approximately $376 billion. Daily trading volume reaches about 29.35 million shares, showing high investor interest in this pharmaceutical giant.
